Back

SGLT2 Inhibitors: diabetes or cardiovascular drugs?

27 August 2018 (13:15 - 13:25)
Organised by:
Congress Presentation Part of: Five things cardiologists should know about diabetes Cardiovascular Disease in Specific Populations ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Lawrence Leiter

University of Toronto, Toronto (Canada)

6 More presentations in this session

Presentation thumbnail
Welcome and opening remarks.
Professor D. McGuire (Dallas, US)
Presentation thumbnail
Diabetes takes a center stage in overall risk for patients with cardiovascular disease .
Doctor A. Gitt (Ludwigshafen, DE)
Presentation thumbnail
Ertugliflozin – A newly emerging SGLT2 inhibitor for patients with type 2 diabetes.
Doctor S. Dagogo-Jack (Memphis, US)
Presentation thumbnail
Questions & Answers.
Professor D. McGuire (Dallas, US) Doctor S. Dagogo-Jack (Memphis, US) Doctor A. Gitt (Ludwigshafen, DE) Professor L. Leiter (Toronto, CA)
Presentation thumbnail
Envisioning the future of SGLT2 inhibitors in the treatment of patients with diabetes and cardiovascular disease: a roundtable discussion.
Doctor A. Gitt (Ludwigshafen, DE) Professor L. Leiter (Toronto, CA) Professor D. McGuire (Dallas, US) Doctor S. Dagogo-Jack (Memphis, US)

Access the full session

Session thumbnail
Five things cardiologists should know about diabetes

The Event

Event poster

ESC Congress 2018

27 August 2018 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Impact of SGLT2 inhibitor on mortality and cardiovascular outcomes in patients with type 2 diabetes mellitus with left main or multivessel coronary artery disease
27 August 2022
thumbnail
Congress Session
Innovative drug therapies in heart failure
18 May 2025
thumbnail
Congress Session
Guidelines in Practice: 2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes
27 August 2023
thumbnail
Congress Presentation
SGLT2i uptake among heart failure patients with reduced ejection fraction: ongoing prescriber hesitancy and how to address this.
29 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources